首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到18条相似文献,搜索用时 187 毫秒
1.
通过注射利血平复制犬脾虚证动物模型,观察犬临床体征、体重及部分血清指标变化情况,并研究针灸对脾虚犬体重及血清指标的影响。结果显示,实验犬出现脾虚证后,其体重显著低于空白对照组(P〈0.05),血清谷丙转氨酶(ALT)、谷草转氨酶(AST)活性与丙二醛(MDA)含量均显著增高(P〈0.05);血清超氧化物歧化酶(SOD)活性显著降低(P〈0.05)。经针灸治疗后,实验组犬各项指标均得到明显改善,与阳性对照组比较呈显著性差异(P〈0.05)。试验结果表明,皮下注射利血平复制犬脾虚证动物模型后,选用一定穴位进行针灸,对治疗犬脾虚证有明显疗效。  相似文献   

2.
通过皮下注射利血平复制犬脾虚证动物模型,观察犬临床体征、体重及部分血清生化指标变化情况,研究四君子汤对脾虚犬体重及血清生化水平的影响。结果显示,在犬出现脾虚证候后,体重与血清总蛋白(TP)、白蛋白(ALB)、球蛋白(GLO)水平均显著低于空白对照组(P0.05);用四君子汤治疗7 d后,脾虚犬体重与血清TP、ALB、GLO均恢复到与空白对照组水平接近,而未经治疗的脾虚试验组犬各项指标未恢复到与空白对照组接近,与空白对照组和四君子汤治疗组比较呈显著性差异(P0.05)。试验结果表明,通过皮下注射利血平可以复制犬脾虚证动物模型,用四君子汤治疗犬脾虚证具有明显的疗效。  相似文献   

3.
以犬为研究对象,探讨黄芪多糖注射液肌肉注射对犬脾虚泄泻证的临床治疗效果。24只健康本地犬饲养1周后灌胃番泻叶水煎剂人工复制脾虚泄泻证病理模型,造模成功后随机分为3组:黄芪多糖注射液治疗组肌肉注射黄芪多糖注射液0.25mL/kg,2次/d;庆大霉素组肌肉注射庆大霉素注射液0.2mL/kg,2次/d;病理对照组不作任何处理;同时设立4头健康犬作为空白对照,造模期间灌胃生理盐水。治愈后检测试验犬体质量、三大临床指标、白细胞、红细胞、血红蛋白及脾脏指数,并进行统计分析。结果表明,黄芪多糖注射液治疗组治愈后白细胞、血红蛋白、红细胞恢复较快,平均日增重及脾脏指数显著高于庆大霉素治疗组(P<0.05);三大临床指标各治疗组差异不显著(P>0.05)。说明黄芪多糖注射液可用于临床治疗动物脾虚泄泻证。  相似文献   

4.
为了研究3种不同银杏叶复方制剂对脾虚证小鼠血清消化酶活性的影响,试验选择体重20~22 g雌性清洁级KM小鼠180只,随机分为10组,每组6个重复,每个重复3只。1~5组分别为空白组、四君子汤组、银杏叶复方Ⅰ组、银杏叶复方Ⅱ组和银杏叶复方Ⅲ组,用于比较四君子汤和3种银杏叶复方制剂对正常小鼠血清消化酶活性的影响;6~10组分别为脾虚证模型组、利血平+四君子汤组、利血平+银杏叶复方Ⅰ组、利血平+银杏叶复方Ⅱ组和利血平+银杏叶复方Ⅲ组,用于研究四君子汤和3种银杏叶复方制剂对利血平所致脾虚证小鼠血清消化酶活性的影响。适应性饲养3 d,试验期15 d,测定脾虚证小鼠血清中淀粉酶(AMS)、脂肪酶(LPS)和胰蛋白酶(TPS)的活性。结果表明:淀粉酶活性6组显著低于1组(P0.05),其他组与1组之间差异不显著(P0.05),6~10组之间差异不显著(P0.05),其中8,10组明显高于其他各组;脂肪酶活性7~10组均显著高于6组(P0.05),8,10组显著高于1组(P0.05);胰蛋白酶活性6~9组显著低于1组(P0.05),6~9组之间差异不显著(P0.05),10组低于1组,但差异不显著(P0.05)。说明3种银杏叶复方和四君子汤都可以在一定程度上提高脾虚证小鼠血清消化酶活性,其中银杏叶复方Ⅲ效果较优,甚至优于四君子汤,可以作为治疗脾虚证后续试验的研究对象。  相似文献   

5.
电针犬后三里穴治疗脾虚泄泻证对其生理指标的影响   总被引:1,自引:0,他引:1  
为验证采用电针犬后三里穴治疗脾虚泄泻证的疗效及探讨其机理。首先,用番泻叶浸剂复制犬脾虚泄泻证病理模型,然后,电针后三里穴,通过测定犬生理常数、血液指标及血浆中丙二醛(MDA)含量的变化,验证其疗效。结果表明,电针犬后三里穴治疗脾虚泄泻证,可以影响脉搏、白细胞数量和血红蛋白含量,降低患犬体温,降低血浆中MDA含量。说明采用电针犬后三里穴治疗脾虚泄泻证效果较明显。  相似文献   

6.
以犬为研究对象,探讨黄芪多糖注射液肌肉注射对犬脾虚泄泻证的临床治疗效果。24只健康本地犬饲养1周后灌胃番泻叶水煎剂人工复制脾虚泄泻证病理模型,造模成功后随机分为3组:黄芪多糖注射液治疗组肌肉注射黄芪多糖注射液0.25mL/kg,2次/d;庆大霉素组肌肉注射庆大霉素注射液0.2mL/kg,2次/d;病理对照组不作任何处理;同时设立4头健康犬作为空白对照,造模期间灌胃生理盐水。治愈后检测试验犬体质量、三大临床指标、白细胞、红细胞、血红蛋白及脾脏指数,并进行统计分析。结果表明,黄芪多糖注射液治疗组治愈后白细胞、血红蛋白、红细胞恢复较快,平均日增重及脾脏指数显著高于庆大霉素治疗组(p〈0.05);三大临床指标各治疗组差异不显著(P〉0.05)。说明黄芪多糖注射液可用于临床治疗动物脾虚泄泻证。  相似文献   

7.
为了研究脾虚证时组织化学的变化及四君子汤对其的影响,选用Wistar大鼠,以利血平复制脾虚证动物模型,实验设正常对照组、脾虚组、脾虚治疗组,每组15只,于第7d、第14d分别扑杀各组动物,取肝脏、十二指肠、胃和肌肉组织,分别应用PAS法和Lojda法染色,组织学半定量法观察糖原和琥珀酸脱氢酶的变化。实验结果表明:第7d时,脾虚组和脾虚治疗组肝脏和肌肉组织中的糖原含量显著低于对照组(P<0.01),各组织中琥珀酸脱氢酶含量则显著高于对照组(P<0.01);第14d时,脾虚组糖原含量反而显著高于对照组和脾虚治疗组(P<0.05~0.01),琥珀酸脱氢酶含量仍明显高于对照组和脾虚治疗组(P<0.050.01)。说明脾虚证的病理变化过程与机体糖原和琥珀酸脱氢酶等的组织化学变化有一定的联系,健脾益气方剂四君子汤对脾虚证模型大鼠的组织学变化有较好的调节作用。  相似文献   

8.
32只健康本地犬饲养1周后按体质量灌胃番泻叶水煎剂6 m L/kg人工复制脾虚泄泻证病理模型,造模成功后随机分为4组:黄芪多糖治疗组后海穴注射黄芪多糖注射液0.25 m L/kg,2次/d;硫酸庆大霉素治疗组后海穴注射硫酸庆大霉素注射液0.2 m L/kg,2次/d;后海穴针刺组后海穴注射生理盐水0.25 m L/kg,2次/d;病理对照组不作任何处理;同时设立4头健康犬作为空白对照,造模期间灌胃生理盐水。用药后治疗期间测定试验犬只的体质量、三大临床指标、部分血液指标和脾脏指数,并统计分析。结果表明,黄芪多糖治疗组血红蛋白、红细胞水平在较短时间内恢复正常,脾脏指数显著(P0.05)高于硫酸庆大霉素治疗组;硫酸庆大霉素治疗组白细胞降低速度极显著(P0.01)快于黄芪多糖治疗组。这表明后海穴注射黄芪多糖注射液可以用于治疗犬脾虚泄泻证。  相似文献   

9.
采用利血平复制脾虚证小鼠模型,观察银杏叶复方对脾虚证小鼠消化酶活性和抗氧化性能的影响。结果表明:与脾虚模型组相比,银杏叶复方能显著提高脾虚证小鼠小肠淀粉酶、脂肪酶和胰蛋白酶活性(P0.05)和血清丙二醛(MDA)含量(P0.01),显著提高脾虚证小鼠血清和肝组织中超氧化物歧化酶(SOD)、谷胱肽过氧化物酶(GSH-Px)活性(P0.05);银杏叶复方组肝脏中总抗氧化能力(T-AOC)含量较脾虚模型组也显著提高(P0.05)。说明银杏叶复方对脾虚证小鼠的消化酶活性有保护作用,并通过降低血清中MDA含量,提高SOD和GSH-Px含量,达到清除自由基,维持膜功能稳定的作用。  相似文献   

10.
为了观察加味四君子汤对脾虚犬的治疗效果,将24只试验犬随机分为正常对照组、脾虚对照组、自然恢复组和加味四君子汤治疗组,采用利血平皮下注射的方法制造脾虚模型,分别检测部分血常规及血生化指标。结果表明:造模后,试验犬血液一些生理生化指标发生明显改变,WBC、RBC、HGB、HCT、MCV、MCH、MCHC、LYM、MON、LY%、MO%、TP、CREA、ALB、GLU、TG、CHO、LDH、Ca、P、Cl均降低,其中LYM、MON、MO%、WBC、TP、GLU、TG、LDH、CL下降显著(P0.05);同时GRA、GR%、RDWc、PLT、MPV、PCT、PDWC、AST、ALT、ALP、GGT、UA、CK均升高,其中GRA、PLT、AST、ALP、GGT、CK升高显著(P0.05);经加味四君子汤治疗后,均可得到较好的恢复,而自然恢复组各指标稍有恢复,但明显不如加味四君子汤治疗组的恢复程度。  相似文献   

11.
A one-year-old female English Cocker Spaniel dog with idiopathic Horner''s Syndrome is described. The specific clinical signs in this specimen were miosis, ptosis, enophthalmos, and prolapsed nictitans for 2 days following sudden onset. According to history taking, ophthalmic, neurological, and radiological examination, the patient was diagnosed with idiopathic Horner''s syndrome. Manual acupuncture treatment was applied to the dog on local points two times in 2 days. The local acupoints were ST-4 (Di Chang) and GB-1 (Tong Zi Liao). The day after the initial acupuncture treatment, clinical signs related to idiopathic Horner''s syndrome had almost disappeared. The day after the second treatment, specific clinical signs were completely absent. During this period, the dog did not receive any orthodox treatment. Thus, it is suggested that manual acupuncture might be an effective therapy for idiopathic Horner''s syndrome.  相似文献   

12.
OBJECTIVE: The syndrome of inappropriate secretion of antidiuretic hormone is a rare disorder in dogs characterised by hypo-osmolality and persistent arginine vasopressin production in the absence of hypovolaemia and/or hypotension. The study describes the efficacy and safety of the nonpeptide selective arginine vasopressin V2 receptor antagonist OPC-31260 in a dog with the naturally occurring syndrome. DESIGN: The detailed case history of a dog with spontaneous syndrome of inappropriate secretion of antidiuretic hormone that received long-term therapy with oral OPC-31260 is presented. Effects of the first dose of OPC-31260 and of a dose administered after a continuous dosing period of 12 days are reported. PROCEDURE: Packed cell volume, plasma sodium, total protein, arginine vasopressin, renin activity, atrial natriuretic peptide, urine specific gravity, urine output, heart rate and body weight were monitored for 2 h before, and for 4 h after, the first dose of OPC-31260. The same parameters plus plasma osmolality and urine osmolality were monitored when an identical dose was administered after 12 days of therapy. RESULTS: Oral administration of OPC-31260 at 3 mg/kg body weight resulted in marked aquaresis with increased urine output and decline in urine specific gravity within 1 h. Corresponding increases in concentrations of plasma sodium, plasma osmolality and plasma renin activity were recorded over a 4 h period. Arginine vasopressin concentration remained inappropriately elevated throughout the study. Results were similar when the trial procedure was repeated after a stabilisation period of 12 days. Long-term therapy with OPC-31260 at a dose of 3 mg/kg body weight orally every 12 h resulted in good control of clinical signs with no deleterious effects detected during a 3-year follow-up period. Despite sustained clinical benefits observed in this case, plasma sodium did not normalise with continued administration of the drug. CONCLUSIONS: Treatment of a dog with naturally occurring syndrome of inappropriate secretion of antidiuretic hormone with OPC-31260 at 3 mg/kg body weight orally every 12 h resulted in marked aquaresis and significant palliation of clinical signs with no discernible side-effects detected over a 3-year period. Thus, OPC-31260 appears to offer a feasible medical alternative to water restriction for treatment of dogs with syndrome of inappropriate secretion of antidiuretic hormone. Higher doses of OPC-31260 may be required to achieve and maintain normal plasma sodium in dogs with this syndrome.  相似文献   

13.
14.
OBJECTIVE: To evaluate the safety of moxidectin administration at doses of 30, 60, and 90 microg/kg of body weight (10, 20, and 30 times the manufacturer's recommended dose) in avermectin-sensitive Collies. ANIMALS: 24 Collies. PROCEDURE: Collies with mild to severe reactions to ivermectin challenge (120 mg/kg; 20 times the recommended dose for heartworm prevention) were used. Six replicates of 4 dogs each were formed on the basis of body weight and severity of reaction to ivermectin test dose. Within replicates, each dog was randomly allocated to treatment with oral administration of 30, 60, or 90 microg of moxidectin/kg or was given a comparable volume of placebo tablet formulation. Dogs were observed hourly for the first 8 hours and twice daily thereafter for 1 month for signs of toxicosis. RESULTS: Signs of toxicosis were not observed in any control group dog throughout the treatment observation period. Likewise, signs of toxicosis were not observed in any dog receiving moxidectin at 30, 60, or 90 microg/kg. CONCLUSIONS AND CLINICAL RELEVANCE: The moxidectin formulation used in the study reported here appears to have a wider margin of safety than ivermectin or milbemycin in avermectin-sensitive Collies.  相似文献   

15.
Objective: To describe the diagnosis and treatment of 2 cases of severe thrombocytopenia associated with splenic torsion and to discuss the pathophysiologic mechanisms underlying the thrombocytopenia. Summary: We report 2 cases of severe thrombocytopenia associated with splenic torsion. Each dog presented with non‐specific clinical signs, radiographic evidence of an intra‐abdominal mass, and platelet counts of less than 25,000 platelets/μL. The diagnosis of splenic torsion was made with abdominal ultrasonography and was confirmed during exploratory laparotomy. Both dogs recovered rapidly following splenectomy. The cause of thrombocytopenia associated with splenic torsion is not fully elucidated, but may be because of either platelet sequestration within the torsed spleen, platelet consumption in disseminated intravascular coagulation, or a combination of both. New information provided: This report provides previously unreported evidence that the degree of thrombocytopenia associated with splenic torsion may be of a severity at which primary hemostasis is compromised, and resolution of thrombocytopenia occurs after splenectomy.  相似文献   

16.
Linda J.  Konde  DVM  Robert H.  Wrigley  BVSc  MS  DVR  Jack L.  Lebel  DVM  PHD  Richard D.  Park  DVM  PHD  Charles  Pugh  DVM  MS  Susan  Finn  DVM 《Veterinary radiology & ultrasound》1989,30(1):41-45
The clinical, radiographic, and sonographic signs in three dogs with splenic torsion are presented. AH dogs exhibited weight loss, anorexia, and lethargy. Splenomegaly was consistent radiographic finding in two dogs and large ill-defined midabdominal mass was seen in one dog. The spleen was easily imaged sonographically in all dogs. Splenic sonography in two dogs showed diffuse, hypoechoic pattern consistent with splenic congestion. Hilar splenic vessels were enlarged on the sonograms of two dogs.  相似文献   

17.
This is the first report of a metallic foreign body in the spleen of a dog. The animal had abdominal discomfort with a tucked-up abdomen and occasional vomition. Radiography and ultrasonography were used to identify a splenic foreign body which was surgically removed through a ventral midline celiotomy. Migration of the foreign body through the stomach wall was suspected as the most likely cause.  相似文献   

18.
In a pharmacokinetic and tolerance study, 2 healthy Beagles were given 13.2 to 39.5 mg of 2-mercaptopropionylglycine (2-MPG)/kg of body weight orally once daily in increasing doses for 3 weeks. A third dog was given 10 mg of 2-MPG/kg of body weight, IV. The drug was well tolerated. After these initial studies, 15 cystinuric dogs were treated with 2-MPG orally once daily for 5 to 45 months and with sodium bicarbonate for urine alkalinization and fluid diuresis. Pharmacokinetic studies were done in 7 dogs on the third day of oral treatment with 2-MPG. After oral administration of 15.6 to 31.3 of 2-MPG/kg of body weight, maximal serum/plasma concentrations were from 28.6 to 76.3/mumol/L after 1 to 3 hours in 6 cystinuric dogs. The mean urinary excretion was 22% (range, 0.3 to 58.9%) of the dose. Ten of 15 cystinuric dogs had no re-formation of uroliths. Of 4 dogs with uroliths at the beginning of treatment, 3 had total urolith dissolution on continuous treatment. During treatment, further growth of the uroliths was inhibited in one dog, and in another dog with re-formed uroliths, they dissolved. We concluded that 2-MPG is well tolerated and promising for treatment of cystinuric dogs, but the pharmacokinetic studies should be expanded to include different dosage regimens, and results of long-term treatment should be evaluated. Our recommendations for treatment of dogs with cystine uroliths include surgical intervention if the dog has urethral obstruction or has dysuria.(ABSTRACT TRUNCATED AT 250 WORDS)  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号